Published by Alexander Bueso on 20th August 2019
(Sharecast News) - Shares of Wall Street biotechnology darling Sarepta Therapeutics came under sharp selling pressure after America's drug safety watchdog rejected the company's petition for accelerated approval of its Golodirsen drug for Duchenne Muscular Distrophy.